Cargando…
The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status
OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette–Guérin (BCG) immunotherapy. METHODS: A search was conducted in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954482/ https://www.ncbi.nlm.nih.gov/pubmed/33763250 http://dx.doi.org/10.1080/2090598X.2020.1791562 |
_version_ | 1783664088976457728 |
---|---|
author | Nowak, Łukasz Krajewski, Wojciech Poterek, Adrian Śliwa, Anna Zdrojowy, Romuald |
author_facet | Nowak, Łukasz Krajewski, Wojciech Poterek, Adrian Śliwa, Anna Zdrojowy, Romuald |
author_sort | Nowak, Łukasz |
collection | PubMed |
description | OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette–Guérin (BCG) immunotherapy. METHODS: A search was conducted in May 2020 of three electronic databases; MEDLINE, Scopus, and EMBASE. In this review we included results from original studies investigating the relationship between the PD-L1 expression and BCG response in patients with NMIBC. RESULTS: Only five relevant articles were identified in the literature to date. Some studies showed an association between increased PD-L1 expression and BCG unresponsiveness; however, other authors provided contradictory results and suggested that PD-L1 evaluation could not be used for reliable prediction of BCG response. CONCLUSIONS: The value of PD-L1 evaluation in predicting BCG response is debatable. Current evidence, based only on retrospective analyses, is inconsistent. Comparability of the results is diminished by the methodological limitations of immunohistochemistry assessment. Further multicentre, randomised trials are needed to make definitive conclusions. ABBREVIATIONS: ICs: immune cells; IHC: immunohistochemical staining; (N)MIBC: (non-) muscle-invasive bladder cancer; PD-L1: programmed cell death protein ligand 1; PD-1: programmed cell death protein 1; RC: radical cystectomy; TCs: tumour cells. |
format | Online Article Text |
id | pubmed-7954482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-79544822021-03-23 The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status Nowak, Łukasz Krajewski, Wojciech Poterek, Adrian Śliwa, Anna Zdrojowy, Romuald Arab J Urol Management of NMIBC OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette–Guérin (BCG) immunotherapy. METHODS: A search was conducted in May 2020 of three electronic databases; MEDLINE, Scopus, and EMBASE. In this review we included results from original studies investigating the relationship between the PD-L1 expression and BCG response in patients with NMIBC. RESULTS: Only five relevant articles were identified in the literature to date. Some studies showed an association between increased PD-L1 expression and BCG unresponsiveness; however, other authors provided contradictory results and suggested that PD-L1 evaluation could not be used for reliable prediction of BCG response. CONCLUSIONS: The value of PD-L1 evaluation in predicting BCG response is debatable. Current evidence, based only on retrospective analyses, is inconsistent. Comparability of the results is diminished by the methodological limitations of immunohistochemistry assessment. Further multicentre, randomised trials are needed to make definitive conclusions. ABBREVIATIONS: ICs: immune cells; IHC: immunohistochemical staining; (N)MIBC: (non-) muscle-invasive bladder cancer; PD-L1: programmed cell death protein ligand 1; PD-1: programmed cell death protein 1; RC: radical cystectomy; TCs: tumour cells. Taylor & Francis 2020-07-16 /pmc/articles/PMC7954482/ /pubmed/33763250 http://dx.doi.org/10.1080/2090598X.2020.1791562 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Management of NMIBC Nowak, Łukasz Krajewski, Wojciech Poterek, Adrian Śliwa, Anna Zdrojowy, Romuald The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status |
title | The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status |
title_full | The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status |
title_fullStr | The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status |
title_full_unstemmed | The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status |
title_short | The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status |
title_sort | prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille calmette–guérin immunotherapy: current status |
topic | Management of NMIBC |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954482/ https://www.ncbi.nlm.nih.gov/pubmed/33763250 http://dx.doi.org/10.1080/2090598X.2020.1791562 |
work_keys_str_mv | AT nowakłukasz theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT krajewskiwojciech theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT poterekadrian theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT sliwaanna theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT zdrojowyromuald theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT nowakłukasz prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT krajewskiwojciech prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT poterekadrian prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT sliwaanna prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus AT zdrojowyromuald prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus |